
Andrew C Charles MD
Headache, Pain Medicine
Professor; and Director, UCLA Goldberg Migraine Program. Meyer and Renee Luskin Chair in Migraine and Headache Studies
Join to view full profile
100 UCLA Medical Plaza, Suite 425Los Angeles, CA 90095
Phone+1 310-794-1195
Fax+1 310-794-1195
Dr. Charles is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
University of California (Irvine)Residency, Neurology, 2019 - 2022
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Neurology, 1987 - 1990
Los Angeles County-Harbor-UCLA Medical CenterInternship, Transitional Year, 1986 - 1987
David Geffen School of Medicine at UCLAClass of 1986
Certifications & Licensure
CA State Medical License 1987 - 2027
American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014, 2016-2017
- America's Top Doctors Castle Connolly, 2009-2014
Clinical Trials
Publications & Presentations
PubMed
- Suzetrigine as a novel treatment for headache disorders: A case series.Molly Fensterwald, Jordan Johnson, Angel Moreno, Shawn Conger-Love, Charles Flippen
Headache. 2026-06-05 - 10 citationsEfficacy and Safety of Eptinezumab in Episodic Cluster Headache: A Randomized Clinical Trial.Rigmor H Jensen, Cristina Tassorelli, Stewart J Tepper, Andrew Charles, Peter J Goadsby
JAMA Neurology. 2025-07-01 - 7 citationsLong-term safety, tolerability, and efficacy of eptinezumab in chronic cluster headache (CHRONICLE): an open-label safety trial.Cristina Tassorelli, Rigmor H Jensen, Peter J Goadsby, Andrew C Charles, Stewart J Tepper
The Lancet. Neurology. 2025-05-01
Press Mentions
New Migraine Prevention Guideline Strays from Expert RecommendationsFebruary 5th, 2025
How to Use Monoclonal Antibodies for Migraine in Primary CareSeptember 24th, 2024
FDA Approves Drug QULIPTA for Chronic MigraineApril 18th, 2023
Grant Support
- A novel platform for the discovery and characterization of migraine therapiesUNIVERSITY OF CALIFORNIA LOS ANGELES2024–2025
- Mechanisms And Functions Of Astrocyte Calcium SignalingNational Institute Of Neurological Disorders And Stroke2000–2004
- MU And Delta Opioid Receptor InteractionsNational Institute On Drug Abuse2002
- Glial Cell Signaling In Central Nervous System InjuryNational Institute Of Neurological Disorders And Stroke1995–1999
- Glial /Neuronal InteractionsNational Institute Of Neurological Disorders And Stroke1995–1999
Other Languages
- Spanish
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:








